Comparison · NCT00089141-d2cd049f
Mycophenolate Mofetil vs Placebo: Recurrent Malignancy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Mycophenolate Mofetil vs Placebo: Recurrent Malignancy. Trial comparisons, record NCT00089141-d2cd049f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00089141-d2cd049f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.23 | 0.149 | 0.337 | wilson | |
| Risk in group 2 | 0.13 | 0.0721 | 0.223 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0999 | -0.0235 | 0.222 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.77 | 0.867 | 3.61 | log | |
| Odds ratio, group 1 over group 2 | 2 | 0.848 | 4.71 | log | |
| Number needed to treat, for one more participant with the outcome on Mycophenolate Mofetil than on Placebo | 10 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Mycophenolate Mofetil | Patients receive oral mycophenolate mofetil 1000 mg twice daily. | 17 | 74 | OG000 |
| Group 2 | Placebo | Patients receive oral placebo twice daily | 10 | 77 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Recurrent Malignancy
- Description
- Development of recurrent malignancy after enrollment in the study
- Time frame
- within 4 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
- NCT number
- NCT00089141
- Phases
- PHASE3
- Conditions
- Cancer
- Interventions
- mycophenolate mofetil, placebo
- Lead sponsor
- Martin, Paul
- Results first posted
- 2009-08-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00089141?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00089141-d2cd049f